From a live demo of PaiX Navigator to the announcement of a new book, PAICON used DMEA as a platform to advance its mission: ensuring medical AI works for the Remaining 84% of the world.
We returned to DMEA this year as recipients of the prestigious Nova Award. The recognition marks a significant milestone for us, but we arrived with more on the agenda than an award. We used the conference to demonstrate our flagship platform, announce an upcoming book, and reinforce a message that has defined us since our founding: the cost of exclusion in medical data is not abstract. It is measurable, and it is urgent.
Putting a Number on the Cost of Exclusion
At the heart of our presence at DMEA was a talk delivered by our CEO & Co-Founder Dr. Manasi A-Ratnaparkhe. Taking the stage as part of the Nova Award programme, she presented a clear-eyed assessment of what it costs when medical data fails to reflect the full diversity of the global population. The figures are significant: an estimated 500,000 lives lost and $5 billion in preventable costs each year, driven by a lack of genetically and technically representative data.
The solution, as Manasi outlined, lies in building medical data infrastructure that reflects not only the 16% of the world currently represented in most clinical datasets, but the remaining 84% as well. That is the problem we were founded to solve, and the work we presented at DMEA reflects how far that work has come.
PaiX Navigator: A Live Look at Global Medical Data
One of the standout moments from our time at DMEA was a live demonstration of PaiX Navigator, our flagship data platform. Drawing from medical datasets across 60+ countries, PaiX Navigator enables clinicians, researchers, and institutions to interact with data conversationally, extract actionable insights, and request tailored datasets based on their specific needs.
The platform is set to enter its beta phase in June 2026. Those interested in early access can submit their interest via the registration form
Remaining84: The Book
We also announced that Manasi has authored a book titled Remaining84, set for publication next month. The book examines the scientific and commercial dimensions of medical data exclusion, building a rigorous case for why inclusive data is not a matter of principle alone, but a prerequisite for effective healthcare systems globally.
Readers can subscribe to be notified upon publication via our mailing list.
Looking Ahead
DMEA 2026 served as a reminder of the growing appetite within the healthcare and health technology community for solutions that take representativeness seriously. The conversations, collaborations, and recognition at this year’s conference reflect a broader shift in how the industry understands the relationship between data quality and patient outcomes.
The work continues. And so does our mission.
